The biological and clinical heterogeneity of neuroblastoma is closely associated with signaling pathways that control cellular characteristics such as proliferation, survival and differentiation. The Shc family of docking proteins is important in these pathways by mediating cellular signaling. In this study, we analysed the expression levels of ShcA and ShcC proteins in 46 neuroblastoma samples and showed that a significantly higher level of ShcC protein is observed in neuroblastomas with poor prognostic factors such as advanced stage and MYCN amplification (Po0.005), whereas the expression level of ShcA showed no significant association with these factors. Using TNB1 cells that express a high level of ShcC protein, it was demonstrated that knockdown of ShcC by RNAi caused elevation in the phosphorylation of ShcA, which resulted in sustained extracellular signal-regulated kinase activation and neurite outgrowth. The neurites induced by ShcC knockdown expressed several markers of neuronal differentiation suggesting that the expression of ShcC potentially has a function in inhibiting the differentiation of neuroblastoma cells. In addition, marked suppression of in vivo tumorigenicity of TNB1 cells in nude mice was observed by stable knockdown of ShcC protein. These findings indicate that ShcC is a therapeutic target that might induce differentiation in the aggressive type of neuroblastomas.
Introduction
Neuroblastoma is the most common pediatric solid tumor derived from the sympathoadrenal lineage of neural crest and its clinical and biological features are heterogeneous. Some types of neuroblastomas show favorable outcomes with spontaneous differentiation or regression by minimum treatment, whereas other types have malignant characteristics with metastasis and resistance to chemotherapy. Age of onset, tumor volume, presence of metastasis, pathological features and amplification of the N-myc gene are important prognostic factors of neuroblastoma. Previously, it was reported that the differential expression of Trk family receptors might contribute to clinical and biological outcomes of neuroblastomas (Nakagawara et al., 1993; Nakagawara and Brodeur, 1997) whereas the cellular signaling involved in the regulation of the aggressiveness of neuroblastoma is largely unknown.
The Shc family of docking proteins is important in signaling pathways mediating the activation of various receptor tyrosine kinases (RTKs) such as the Trk family triggered by extracellular stimulations, to specific downstream molecules. The Ras-extracellular signal-regulated kinase (ERK) pathway and the phosphoinositide-3 kinase (PI3K)-Akt pathway are the most common signals regulated by Shc family proteins, representing important functions in cellular proliferation, survival and differentiation.
The Shc family has three members, ShcA/Shc, ShcB/ Sli/Sck and ShcC/Rai/N-Shc encoded by different genes (Nakamura et al., 1996; O'Bryan et al., 1996; Pelicci et al., 1996) . ShcA protein having three protein isoforms, p46, p52 and p66, is ubiquitously expressed in most organs except the adult neural systems, whereas ShcC (p52 and p67 isoforms) are exclusively expressed in the neuronal system (Sakai et al., 2000) . In the central nervous system, ShcA expression is most significant during embryonic development with sudden decrease after birth. On the other hand, ShcC expression is remarkably induced around birth and maintained in the mature brain. The Shc family molecules have a unique PTB-CH1--SH2 modular organization with two phosphotyrosine-binding modules, PTB and SH2 domains, which recognize various phosphotyrosine-containing peptides with different specificities. CH1 domains contain several tyrosine phosphorylation sites that recruit other adaptor molecules such as Grb2. Functional analysis of ShcB and ShcC on the neuronal signal pathway indicate that these proteins in neuronal cells potentially regulate epidermal growth factor (EGF) or nerve growth factor (NGF) signaling in a similar fashion to ShcA (O'Bryan et al., 1996; Nakamura et al., 1998) .
Major parts of neuroblastoma cell lines show the expression and tyrosine phosphorylation of ShcC protein, but its effect on the biology of tumor cells remains to be elucidated. We have recently shown that constitutive tyrosine phosphorylation of ShcC is induced in a subset of neuroblastoma cells by the activation of anaplastic lymphoma kinase (ALK) owing to ALK gene amplification and the constitutively activated ALK-ShcC signal pathway could induce cell survival, anchorage-independent growth of the cells and progression of tumors (Miyake et al., 2002 . In our study, significant amplification of ALK was observed in 3 of 13 neuroblastoma cell lines and in only 1 of 85 cases of human neuroblastoma samples (Osajima-Hakomori et al., 2005) . Considering these results, it was suspected ShcC might also contribute to the signal pathway associated with the tumor behavior in ALK-independent manners in majority of neuroblastoma cells.
In a recent report, high expression of ShcC mRNA was shown to be a poor prognostic factor in neuroblastoma patients through the semiquantitative reverse transcriptase -PCR analysis of tissue samples (Terui et al., 2005) , suggesting the possibility that ShcC protein might be causative of tumor progression in neuroblastoma patients. In the current study, we examined the expression levels of ShcC protein in tumor samples of 46 neuroblastoma patients and confirmed the significant association of the expression levels of ShcC protein with several factors linked to unfavorable outcome of neuroblastoma. Furthermore, we investigated the functions of ShcC in cell proliferation, differentiation and in vivo tumorigenicity of neuroblastoma cells by knockdown of ShcC expression in neuroblastoma cell lines expressing a high level of ShcC without ALK amplification.
Results
Expression and tyrosine phosphorylation of ShcC in neuroblastoma cell lines At first, the expression of ShcA and ShcC was analysed in 11 neuroblastoma cell lines using each specific antibody (Supplementary Figure A) along with DLD-1 as a control, which is known to express ShcA protein (mainly p46ShcA and p52ShcA), but not ShcC protein ( Figure 1a ). The three cell lines with ALK gene amplification (NB-39-n, Nagai and NB-1: Group A) expressed ShcC at a moderate level in contrast to their significant phosphorylation so that ALK-ShcC complex is mediating the dominant oncogenic signal (Miyake et al., 2002; Osajima-Hakomori et al., 2005) . Other 2   1  5  9  13  17  21  25  29  33  37  41  45   1  5  9  13  17  21  25  29  33  37  41 Figure 1A , middle panel). In contrast to ShcC, the expression of ShcA was within similar levels among neuroblastoma cell lines ( Figure 1A , lower panel). (Brodeur and Nakagawara, 1992; Ohira et al., 2003) . The expression level of ShcA and ShcC in western blotting was standardized by intensity of a-tubulin within each filter, standardized by the amounts in TNB-1 cells as an internal control among different filters and statistically evaluated from at least two independent western blots for each sample (Table 1) . We found that there is a significant difference in the expression levels of ShcC among the subsets of neuroblastomas. In the group of type II and type III, the expression level of ShcC protein was substantially higher than that in the type I group (Figure 1Ba ). Both isoforms of ShcC, p52ShcC and p67ShcC, showed similar patterns of expression. As shown in Figure  1Ba ). The results of representative samples from each subset are shown in Figure 1Bb . These data indicate that the expression of ShcC protein is significantly associated with multiple prognostic factors of neuroblastoma, suggesting that ShcC has specific functions in malignant phenotypes of neuroblastoma presumably by modulating cellular signaling.
Biological effects of ShcC downregulation on TNB-1 cells
To elucidate the biological functions of ShcC in the tumor characteristics causing unfavorable outcomes of neuroblastoma patients, we investigated the effects of ShcC knockdown on the cellular biology and signal transduction in one of the neuroblastoma cell lines, TNB-1, which expresses a high level of ShcC protein with no ALK amplification. The expression of ShcC and ShcA was suppressed by RNA interference using two independent sets of specific small interfering RNA (siRNA) oligonucleotides corresponding to ShcC and ShcA, respectively (Figure 2Aa ). The growth rate of TNB-1 cells transfected with the ShcA siRNA was severely suppressed (Figure 2Ab ), owing to impaired ability of proliferation and survival, which is consistent with previous reports (Ravichandran, 2001) . ShcC-knockdown cells showed a relatively weak effect on growth rate in the normal culture condition ( Figure 2Ab ).
Downregulation of ShcC induces neurite outgrowth and increases differentiation-related markers in TNB-1 cells
ShcC knockdown caused morphological changes to rather flat and spindle shape and neurite extension within 24 h after transfection of ShcC siRNA ( Figure  2Ba ). These neurite-bearing cells express higher amount of microtubule-associated protein 2 (MAP-2), growthassociated protein 43 (GAP-43), a protein expressed in the growing neurites, and chromogranin A (Chr-A; Figure 2Bb ), markers of neuronal differentiation (Giudici et al., 1992) than the control cells. On the other hand, TNB-1 cells treated with ShcA siRNAs showed no remarkable change compared with the control cells, relatively round with small processes attached to the dish surface ( Figure 2Ba ). These results suggest that the endogenous ShcC negatively affects neurite outgrowth and differentiation of TNB-1 cells.
Persistent activation of ERK1/2 due to ShcC downregulation induces neurite outgrowth in TNB-1 cells Neuronal differentiation is closely associated with mitogen-activated protein kinase (MAPK)/ERK kinase (MEK)/ERK and PI3K-AKT pathways and both of them might be controlled downstream of Shc family signaling. Downregulation of ShcA induced the suppression of extracellular signal-related kinase 1/2 (ERK1/2) and AKT pathways at 48 h after transfection of siRNA, nevertheless ShcC downregulation apparently elevated the base level of ERK phosphorylation and slightly enhanced AKT activation ( Figure 3a ). This elevation of ERK phosphorylation sustained until 96 h after transfection of siRNA. Similar effect on the ERK activation was also observed in NH-12 and YT-n cells, which express high amount of ShcC (Supplementary Figure B) . It is reported that sustained activation of ERK is responsible for neurite outgrowth and differentiation of PC12 cells (Qui and Green, 1992) . To investigate whether neuronal extension of TNB-1 cells by ShcC RNAi was induced by sustained activation of ERK, the effect of MEK inhibitor, PD98059, on the differentiation of TNB-1 cells by knockdown of ShcC was examined. It was found that inhibition of the ERK pathway abolished the neurite outgrowth of TNB-1 cells by ShcC knockdown, indicating that ShcC protein has the potential to suppress neurite outgrowth which is dependent on the sustained activation of the ERK pathway ( Figure 3b ). In addition, the sustained activation of ERK by the expression of activated Raf protein, RafCAAX (Leevers et al., 1994; Stokoe et al., 1994) also induced neurite outgrowth in TNB-1 cells (Supplementary Figure C) just as in PC12 cells (Dhillon et al., 2003) . We also analysed the effect of PI3K inhibitor on neurite outgrowth induced by ShcC RNAi to check the involvement of the PI3K-AKT pathway, whereas no apparent effects on the number and length of the neurite extension were observed (Supplementary Figure D) .
Effect of ShcC knockdown on ERK activation is enhanced by collagen stimulation by ShcA-Grb2 signaling Among several culture conditions of cells examined for the effect of ShcC RNAi on the activity of ERK, the most obvious activation of ERK was observed after the In contrast, ERK activation was consistently suppressed by knockdown of ShcA regardless of these culture conditions (Figure 4a, upper panel) .
Integrins-mediated extracellular signaling lead the activation of Ras/ERK signaling by ShcA, and that process is reported to be associated with Src family kinase (Wary et al., 1996 (Wary et al., , 1998 , focal adhesion kinase (Hecker et al., 2002) or some RTKs (Moro et al., 1998; Hinsby et al., 2004) . In TNB-1 cells, enhanced ShcA phosphorylation and ShcA-Grb2 complex formation was observed following collagen stimulation and further increased by ShcC RNAi (Figures 4b and c) . To examine whether the phosphorylation of ShcA is necessary for the neurite formation, the effect of double knockdown of both ShcC and ShcA was examined in TNB-1 cells. ERK activation and neurite outgrowth were not detected in the absence of both ShcC and ShcA, indicating that ShcC RNAi-induced neurite outgrowth of TNB-1 cells might be dependent on the ShcA expression in adherent state (Figure 4d ).
Expression of ShcC suppresses the phosphorylation of ShcA in KU-YS cells stimulated by EGF
To further analyse the effects of ShcC expression on ShcA phosphorylation in neuroblastoma cells, we introduced a vector expressing p52ShcC into KU-YS neuroblastoma cells, which do not express a detectable amount of endogenous ShcC protein ( Figure 1A ), and obtained several stable clones expressing p52ShcC at different levels ( Figure 5a ). As controls, clones overexpressing p46/p52ShcA, or expressing the expression vector alone were also prepared. We checked the ShcA phosphorylation of each clone under the stimulation of EGF (Figure 5b ). EGF stimulation to the control and ShcA expressing cells showed typical activation of ShcA, whereas the cell expressing ShcC showed decreased levels of ShcA phosphorylation according to the levels of ShcC protein. We also confirmed that activation of ShcA by EGF was suppressed in the cells transiently overexpressing ShcC (Supplementary Figure F) . Those cells showed almost the same level of EGF receptor (EGFR) activation induced by EGF, judging from the phosphorylation levels of EGFR indicating that the expression of ShcC negatively affected the EGFR-ShcA signaling after the activation of EGFR, such as competing manners against ShcA. In addition, we examined whether tyrosine phosphorylation of ShcC is crucial for the suppression of ShcA phosphorylation by establishing two clones that express a p52ShcC mutant, 3YF lacking all three tyrosines, which are reported to be involved in the tyrosine phosphorylation of ShcC . It was revealed that the 3YF mutant of ShcC could suppress the EGF-induced activation of ShcA in both clones almost as efficiently as the original ShcC in ShcC2 cells (Supplementary Figure G) , suggesting that negative regulation of ShcA phosphorylation by ShcC does not require tyrosine phosphorylation of ShcC.
ShcC downregulation negatively affects anchorageindependent growth and in vivo tumorigenicity We investigated the effect of ShcC knockdown on the anchorage-independent growth and in vivo tumorigenicity of TNB-1 cells by establishing cells with stable suppression of ShcC expression using the miR RNAi expression vector (as described in 'Materials and methods'). As analysed in the mixed clones by soft agar colony formation assay, stable suppression of ShcC caused marked inhibition of anchorage-independent growth (Figure 6a ). Three isolated clones of ShcC miR 
Discussion
It has already been shown that some signal pathways strongly affect tumor progression and treatment resistance (Schwab et al., 2003) . Other than the Trk family, the PI3K/Akt pathway (Opel et al., 2007) , Ret (Iwamoto et al., 1993; Marshall et al., 1997) , hepatocyte growth factor/c-Met pathway (Hecht et al., 2004) were reported to be closely associated with several diagnostic profiles and biological characteristics of neuroblastoma cells. This is the first study to show that the expression of ShcC protein, a member of the Shc family docking proteins, is significantly correlated with malignant phenotypes associated with advanced neuroblastoma. Expression of both p52 and p67 isoforms of ShcC, immunostaining of neuritis as described in 'Materials and methods'; right panel: western analysis using indicated antibodies). As a positive control of differentiation, 2.5 mM retinoic acid (RA) was treated 24 h before analysis. AR1, AR2/CR1, CR2: two independent siRNA of ShcA /ShcC; Li: treated with only Lipofectamine 2000; ac1, ac2/cc1, cc2: control siRNA for ShcA /ShcC siRNA, respectively. NC: negative control for universal siRNA (as described in 'Materials and methods').
shows significant correlation with clinical stage and MYCN gene amplification whereas the expression of both isoforms of ShcA, p52 and p66, showed little association with those aspects. These results, in the protein level, give further evidence that ShcC is a factor which determines the prognosis of neuroblastoma, which was recently suggested by analysis of the mRNA expression of ShcC (Terui et al., 2005) .
The biological analysis of TNB-1 cells treated with ShcC-specific siRNAs provided evidence that ShcC protein expressed in the neuroblastoma cells is suppressing the differentiation of neuroblastoma cells. Neurite outgrowth of TNB-1 cells, induced by downregulation of ShcC was dependent on sustained activation of the MEK/ERK pathway. Sustained activation of the ERK pathway triggered by factors such as NGF is required for neuronal differentiation in some neuronal tumor cells such as PC12 cells (Qui and Green, 1992; Yaka et al., 1998) . The fact that constitutively activated Raf-ERK signaling induced neurite outgrowth in the same cell line (Supplementary Figure C) , such as the RTKrelated pathway might induce the ERK activation and cellular differentiation in TNB-1 cells, although NGF stimulation failed to induce neurite elongation of TNB-1 cells (data not shown). Interestingly, elevation in the level of phosphorylated ShcA followed by activation of the ERK pathway by ShcA-Grb2 signals was observed in TNB1 when the ShcC protein expression was suppressed by RNAi. This activation of the ShcA-Grb2-ERK pathway caused by downregulation of ShcC may be due to a competitive effect between ShcC and ShcA for binding to certain RTKs. This possibility is supported by another experiment showing that both EGF-induced phosphorylation of ShcA and complex formation between ShcA and Grb2 in KU-YS cells are suppressed by the expression of ShcC in a dose-dependent manner. It was shown that the expression of the PTB domains of ShcC partially interfered with the binding of endogenous ShcA to activated EGFR in 293 cells (O'Bryan et al., 1998) . These data are consistent with our current findings described above. It is suspected that some types of differentiation signals mediated by ShcA are blocked by the overexpression of ShcC in some neuroblastoma cells such as TNB-1, and the suppression of ShcC protein by RNAi causes the ShcA-mediated differentiation of these cells.
Elevated level of ShcA phosphorylation and ERK activation induced by ShcC downregulation was more significant under the stimulation of collagen I than without any ECM stimulation. In addition, in suspending condition we could not detect any activation of ShcA nor ERK signal after ShcC downregulation (Supplementary Figure E) . These results indicate that the difference between ShcA and ShcC might be in interaction with matrix-adhesion signals. ShcA is considered to be implicated in the adherent related pathway, phosphorylated by forming a complex with Fyn (Wary et al., 1998) through its proline-rich region that is not conserved in ShcC.
In tissue culture and in transgenic mice, signaling through Fyn has been closely associated with neurite extension and cell adhesion (Brouns et al., 2000 (Brouns et al., , 2001 . Berwanger et al. (2002) referred to the inverse correlation between the expression of Fyn and progression of neuroblastoma from 94 primary neuroblastoma specimens, showing that expressed Fyn-induced differentiation and growth arrest of neuroblastoma cell lines. Another report indicated that active Fyn kinase induces a lasting activation of the MAPK pathway through inhibition of MAPK phosphatase 1 (Wellbrock et al., 2002) . We confirmed that neurite outgrowth of ShcCknockdown TNB-1 cells was suppressed by Src family inhibitor, PP2 (Supplementary Figure H) . These data suggest the possibility that Integrin-Fyn-ShcA signals could be closely associated with the differentiation of TNB-1 cells induced by ShcC downregulation along with the signals of RTK-ShcA/ShcC.
Noticeably, the interference of the ShcA-mediated signaling by ShcC protein is independent of tyrosine phosphorylation of ShcC. The function of the nonphosphorylated domain of ShcC such as SH2 might be also highlighted. As for the difference in the downstream signaling between ShcC and ShcA, little is known so far. Regarding to this point, Nakamura et al. (2002) indicated that inhibition of NGF-induced ERK activation by the expression of ShcC was due to the different Grb2-binding capacity between ShcA and ShcC in response to NGF. It was previously reported that ShcA preferentially binds to TrkA (Yamada et al., 2002) , which is the key receptor against NGF due to neurite outgrowth with the sustained ERK phosphorylation, ShcC in differentiation of neuroblastoma I Miyake et al whereas ShcC associated with TrkB rather than TrkA (O'Bryan et al., 1998; Liu and Meakin, 2002) . In neuroblastoma, the function of signal pathways downstream of these two neurotrophin receptors might be quite different (Nakagawara et al., 1993) , also suggesting the distinct function of downstream signal mediated by ShcC.
The effect of ShcC knockdown in in vivo tumorigenicity was quite remarkable comparing the effect in growth rate in tissue culture condition. We found that anchorage-independent growth in cells was also dramatically decreased by knockdown of ShcC as shown by soft agar assay (Figure 6a) . Furthermore, the proportion of apoptotic cells in the nude mouse tumors generated from neuroblastoma cells in vivo was remarkably increased by the knockdown of ShcC. In recent study, Magrassi et al. (2005) showed that ShcC positively effects on cell survival by PI3K-AKT pathway in glioma cells using dominant negative form of ShcC. Theses data indicate that ShcC has additional function in the protection from some types of apoptosis in addition to the induction of differentiation of cells.
It was indicated that ShcC might have a potent function for tumor progression in neuroblastoma by suppressing the differentiation and by promoting the anchorage-independent growth in the majority of neuroblastoma cells which has high expression of ShcC protein. From these points of view, we suggest that ShcC is a potent tool for predicting the phenotype of neuroblastoma and is also a good candidate for therapeutic targets of advanced neuroblastoma.
Materials and methods
Cell culture and tissue samples DLD-1 cells and all cell lines of neuroblastomas in this study were prepared as described in the previous report (Miyake et al., 2002) . These cells were cultured in an RPMI 1640 medium with 10% fetal calf serum (FCS) (Sigma, St Louis, MO, USA) at 37 1C in an atmosphere containing 5% CO 2 .
Anonymous 46 frozen neuroblastoma tissues were used in this study. The samples were divided into three subsets using Brodeur's classification; type I (stage 1, 2 or 4S; a single copy of MYCN), type II (stage 3 or 4; a single copy of MYCN) and type III (all stages; amplification of MYCN) (Brodeur and Nakagawara, 1992; Ohira et al., 2003) . A total of 15 samples belonged to type I, 18 samples to type II and 13 samples to type III. Staging classification was according to the International Neuroblastoma Staging System and N-Myc amplification (>10 copy) accepted as a poor prognostic risk factor was checked before clinical intervention.
Reagents
The polyclonal antibodies against the CH1 domain of human ShcC (amino acid 225-324):ahShcC were generated by the same method as described previously (Miyake et al., 2002) . Polyclonal antibodies of human ShcA:ahShcA were prepared as described in previous reports (Miyake et al., 2002) .
Other antibodies were purchased as follows: antiphosphotyrosine antibody (4G10) (Upstate Biotechnology Inc., Charlottesville, VA, USA), anti-ShcA/ShcC monoclonal antibodies: aShcA/aShcC (BD Transduction Laboratories, San Diego, CA, USA), anti-a-tubulin antibody (Zymed Laboratories, San Francisco, CA, USA), anti-p44/42 MAPK (ERK1/2), antiphospho-p44/42 MAPK (P-ERK1/2), anti-Akt, and antiphospho-Akt (Ser473) (P-Akt) antibodies (Cell Signaling, Danvers, MA, USA), anti-chromogranin A (ChrA) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GAP43 antibody (Zymed Laboratories), anti-MAP2 antibody (Santa Cruz Biotechnology), anti-c-Src antibody (Upstate Biotechnology Inc.), anti-phospho-Src family antibody (Tyr416) (Cell Signaling), anti-Grb2 antibody (BD Transduction Laboratories), anti-T7tag antibody (Novagen, San Diego, CA, USA) and anti-Flag M2 antibody (Sigma). As secondary antibodies, horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgGs (GE Healthcare, Buckinghamshire, UK) were used. All inhibitors used in this study (PD98059, LY294002, PP2 and PP3) were purchased from Calbiochem, San Diego, CA, USA.
Cell stimulation, immunoprecipitation and immunoblotting
Cell stimulation analysis with EGF (Wako) was performed as described (Miyake et al., 2002) . The cells were starved for 24 h and treated for 5 min with EGF (100 ng/ml). As for stimulation with collagen type I, cultured cells with or without serum for 24 h were detached from culture dishes by pipette treatment and after the suspending condition for 30 min, seeded onto a collagen type I-coated dish (Iwaki, Tokyo, Japan). Cells were harvested after 2 h using PLC lysis buffer. Control cells were harvested before the attachment on the collagen I-coated surface. The immunoprecipitation and western analysis were performed using the procedure described in a previous report (Miyake et al., 2002) .
Quantification and statistical analysis of expression levels of ShcC/ShcA The intensity of each band obtained by western analysis was measured using a molecular imager (GS-800; Bio-Rad, Hercules, CA, USA) and standardized according to control signals, such as the bands of TNB-1 and a-tubulin.
t-Test performed by Excel was used to evaluate the significance of the two groups quantified expression levels of indicated molecules.
Knockdown of ShcA/ShcC by RNA interference For siRNAs, Stealth RNA duplex oligoribonucleotides (Invitrogen, Carlsbad, CA, USA) was used to knockdown ShcC/ShcA protein. The following two 25-mer oligonucleotide pairs for each molecule were available. As for ShcC, CR1: 5 0 -GCUGGCCAAAGCGCUCUAUGACAAU-3 0 (nucleotides 141-165), CR2: 5 0 -CCAAGAUCUUUGUGGCGCACA GCAA-3 0 (nucleotides 2447-2471). As negative controls for each oligonucleotide pair, cc1: GGCUCCAGAACGGCCUUAGU AACAU-3 0 , cc2: GGAAACCGACAACUACGAUGUCAAU, respectively. As for ShcA, AR1: 5 0 -GGAGUAACCUGAA AUUUGCUGGAAU-3 0 (nucleotides 335-359). AR2: 5 0 -GCCU UCGAGUUGCGCUUCAAACAAU-3 0 (nucleotides 689-611). As a negative control for each, ac1: GGAAACCGUAAUAUU CGGUGUGAA, ac2: 5 0 -UGCCGCGAUUCGCGUUACAAC UUAAU, respectively. As the other negative control for universal siRNA, Stealth RNAi Negative Control Duplexes (Medium GC Duplex) (Invitrogen) was used (NC). Cells were transfected with siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cells (5 Â 10 5 per well of a six-well plate) in suspending condition were transfected twice at 24 h interval (5 ml of 20 mM siRNA each) and analysed 48 h after second transfection.
A system stably expressing miRNA was generated using the BLOCK-iT Pol II miR RNAi Expression Vector Kit with EmGFP (Invitrogen) according to the manufacturer's instructions. In the generation of the miR RNAi vector for humans, ShcC was chosen as the target sequence, using the top/bottom oligo sequence: 5 0 -TGCTGCTTGGAGGCTTTCTCTTCTT GGTTTTGGCCACTGACTGACCAAGAAGAAAGCCTC CAAG-3 0 /5 0 -CCTGCTTGGAGGCTTTCTTCTTGGTCAGTC AGTGGCCAAAACCAAGAAGAGAAAGCCTCCAAGC-3 0 . Cells stably expressing the miR RNAi vector for ShcC (miShcC) and LacZ (miLacZ), that were also expressing green fluorescent protein were established and cultured in medium containing blasticidin (InvivoGen, San Diego, CA, USA) at a concentration of 15 mg/ml for 3 weeks. Three clones expressing the ShcC RNAi vector were selected by significant suppression of the ShcC protein (o10%), and two clones from the control LacZ vector were also selected. Cells transfected with miRnegative control plasmid (one of kit components) were used as other control cells (Vec).
Generation of KU-YS cells stably expressing ShcA/ShcC
The full-length human ShcA cDNA for transfection was donated by Dr N Goto. ShcA and ShcC cDNAs were inserted with C-terminal Flag epitope tag into a mammalian expression vector pcDNA3.1A. All parts amplified by PCR were verified by sequencing. The stable expression of the full-length of ShcA and full-length of ShcC in KU-YS cells were obtained by transfection using transfection reagent Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The KU-YS cells transfected with pcDNA3.1 vector (mock) were used as a control. Then, cells were selected according to the method described previously and the expression level of each independent clone was evaluated by immunoblotting analysis.
